<code id='29E314D158'></code><style id='29E314D158'></style>
    • <acronym id='29E314D158'></acronym>
      <center id='29E314D158'><center id='29E314D158'><tfoot id='29E314D158'></tfoot></center><abbr id='29E314D158'><dir id='29E314D158'><tfoot id='29E314D158'></tfoot><noframes id='29E314D158'>

    • <optgroup id='29E314D158'><strike id='29E314D158'><sup id='29E314D158'></sup></strike><code id='29E314D158'></code></optgroup>
        1. <b id='29E314D158'><label id='29E314D158'><select id='29E314D158'><dt id='29E314D158'><span id='29E314D158'></span></dt></select></label></b><u id='29E314D158'></u>
          <i id='29E314D158'><strike id='29E314D158'><tt id='29E314D158'><pre id='29E314D158'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:1
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In